Previous 10 | Next 10 |
2023-08-14 08:31:57 ET United States Steel ( X ) +28% explores strategic alternatives after rejecting Cleveland-Cliffs offer . AMC Entertainment Holdings ( APE ) +25% . Genius Group ( GNS ) +21% . Eloxx Pharmaceuticals ( ELOX ) +26% r ...
BERKELEY, Calif. and MAINZ, Germany, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that London-based Marylebo...
2023-07-18 05:42:11 ET Mainz Biomed ( NASDAQ: MYNZ ) entered commercial partnership for ColoAlert with Fugene Genetics, a renowned genetic testing service provider based in Israel. Fugene Genetics, established in 2008, offers a wide range of advanced genetic testing servic...
BERKELEY, Calif. and MAINZ, Germany, July 18, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“MainzBiomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today its commercial partnership ...
BERKELEY, Calif. and MAINZ, Germany, June 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it has entered into a...
BERKELEY, Calif. and MAINZ, Germany, June 28, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in early cancer detection, is thrilled to announce its participation in the ...
ColoAlert ® will be offered to an addressable market of 6 million patients through 15 laboratories. BERKELEY, Calif. and MAINZ, Germany, June 20, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular ...
2023-05-31 06:19:06 ET Mainz Biomed ( NASDAQ: MYNZ ) on Wednesday notifies the establishment of a commercial partnership for ColoAlert ® with TESTDNA Sp. z o.o. Sp. k. Katowice in Poland. ColoAlert, Mainz Biomed’s flagship product, is a high...
Total addressable market in Poland is estimated at 21 million patients BERKELEY, Calif. and MAINZ, Germany, May 31, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializin...
Employees found the online patient portal, through which they ordered the ColoAlert ® test, easy-to-use and convenient BERKELEY, Calif. and MAINZ, Germany, May 24, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company ...
News, Short Squeeze, Breakout and More Instantly...
BERKELEY, Calif. and MAINZ, Germany, July 25, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in early detection of cancer, today announced significant improvements to its ColoAlert product, currently being commercialized across Euro...
--News Direct-- Mainz BioMed CEO Guido Baechler joined Steve Darling from Proactive to announce the company has submitted an application to the U.S. Food and Drug Administration requesting Breakthrough Device Designation for its innovative non-invasive Next Generation colorectal cancer sc...
On the basis of its positive clinical studies Mainz Biomed has now defined the final configuration including its novel mRNA biomarkers of the Next Generation Test to be used in pivotal registration study ReconAAsense A recent clinical analysis of this new configuration demonstrates sens...